HMOs See Optimum Co-Pay For Branded Rxs At Over $20 - Novartis Report
Executive Summary
HMO pharmacy directors put the "optimum" co-payment for a just-introduced, branded Rx drug at $20.70, IMS VP-Communications Robin Emigh noted in a preview of the 1999 edition of Novartis' Pharmacy Benefit Report.